 | Up a level |
Mathier, Etienne; Althaus, Alexander; Zwahlen, Daniel; Lustenberger, Jens; Zamboglou, Constantinos; De Bari, Berardino; Aebersold, Daniel M; Guckenberger, Matthias; Zilli, Thomas; Shelan, Mohamed (2024). HypoFocal SRT Trial: Ultra-hypofractionated focal salvage radiotherapy for isolated prostate bed recurrence after radical prostatectomy; single-arm phase II study; clinical trial protocol. BMJ open, 14(e075846) BMJ Publishing Group 10.1136/bmjopen-2023-075846
Adebahr, Sonja; Althaus, Alexander; Scharl, Sophia; Strouthos, Iosif; Farolfi, Andrea; Serani, Francesca; Lanzafame, Helena; Trapp, Christian; Koerber, Stefan A; Peeken, Jan C; Vogel, Marco M E; Vrachimis, Alexis; Spohn, Simon K B; Grosu, Anca-Ligia; Kroeze, Stephanie G C; Guckenberger, Matthias; Fanti, Stefano; Hruby, George; Emmett, Louise; Belka, Claus; ... (2024). The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy. European journal of nuclear medicine and molecular imaging, 51(2), pp. 558-567. Springer 10.1007/s00259-023-06438-3
Ermiş, Ekin; Althaus, Alexander; Blatti, Marcela; Uysal, Emre; Leiser, Dominic; Norouzi, Shokoufe; Riggenbach, Elena; Hemmatazad, Hossein; Ahmadli, Uzeyir; Wagner, Franca (2023). Therapy Resistance of Glioblastoma in Relation to the Subventricular Zone: What Is the Role of Radiotherapy? Cancers, 15(6) MDPI AG 10.3390/cancers15061677
Mathier, Etienne; Dervishi, Gezim; Althaus, Alexander Maria Georg; Schanne, Daniel Hendrik; Aebersold, Daniel Matthias; Shelan, Mohamed (17 January 2023). Risk of bleeding following robotic stereotactic body radiation therapy in patients with localized prostate cancer in patients receiving baseline anticoagulant or antiplateletherapy. Strahlentherapie und Onkologie, p. 225. Springer
Shelan, Mohamed; Althaus, Alexander Maria Georg; Mathier, Etienne; Schanne, Daniel Hendrik; Aebersold, Daniel Matthias (17 January 2023). Biochemical control after robotic stereotactic body radiation therapy for unfavorable intermediate and high-risk prostate cancer: a single institutional experience with mid-term followup. Strahlentherapie und Onkologie, p. 225. Springer
